- Home
- OCFC vs COGT Comparison
OCFC vs COGT Comparison
Compare OCFC & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- COGT
- Stock Information
- Founded
- OCFC 1902
- COGT 2014
- Country
- OCFC United States
- COGT United States
- Employees
- OCFC N/A
- COGT N/A
- Industry
- OCFC Major Banks
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- COGT Health Care
- Exchange
- OCFC Nasdaq
- COGT Nasdaq
- Market Cap
- OCFC 983.2M
- COGT 817.5M
- IPO Year
- OCFC 1996
- COGT 2018
- Fundamental
- Price
- OCFC $18.54
- COGT $11.19
- Analyst Decision
- OCFC Buy
- COGT Strong Buy
- Analyst Count
- OCFC 4
- COGT 9
- Target Price
- OCFC $21.25
- COGT $19.38
- AVG Volume (30 Days)
- OCFC 305.8K
- COGT 4.7M
- Earning Date
- OCFC 07-24-2025
- COGT 08-05-2025
- Dividend Yield
- OCFC 4.21%
- COGT N/A
- EPS Growth
- OCFC N/A
- COGT N/A
- EPS
- OCFC 1.53
- COGT N/A
- Revenue
- OCFC $369,879,000.00
- COGT N/A
- Revenue This Year
- OCFC N/A
- COGT N/A
- Revenue Next Year
- OCFC $12.29
- COGT N/A
- P/E Ratio
- OCFC $12.42
- COGT N/A
- Revenue Growth
- OCFC N/A
- COGT N/A
- 52 Week Low
- OCFC $14.29
- COGT $3.72
- 52 Week High
- OCFC $21.87
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- OCFC 61.22
- COGT 87.74
- Support Level
- OCFC $18.47
- COGT $7.07
- Resistance Level
- OCFC $19.19
- COGT $10.23
- Average True Range (ATR)
- OCFC 0.42
- COGT 0.66
- MACD
- OCFC 0.11
- COGT 0.37
- Stochastic Oscillator
- OCFC 75.38
- COGT 99.89
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.